These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1003 related articles for article (PubMed ID: 21507715)

  • 21. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
    Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
    Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
    Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
    Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous bortezomib: a step towards optimised drug use.
    Mateos MV
    Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
    [No Abstract]   [Full Text] [Related]  

  • 26. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
    Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; San-Miguel JF; Bladé J; Boccadoro M; Cavenagh J; Dalton WS; Boral AL; Esseltine DL; Porter JB; Schenkein D; Anderson KC;
    N Engl J Med; 2005 Jun; 352(24):2487-98. PubMed ID: 15958804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
    Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
    Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
    [No Abstract]   [Full Text] [Related]  

  • 28. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
    Moore S; Atwal S; Sachchithanantham S; Streetly M; Khan I; Percy L; Narat S; D'Sa S; Rabin N; Johnston R; Schey S; Yong K
    Eur J Haematol; 2013 May; 90(5):420-5. PubMed ID: 23294279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
    Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
    Bringhen S; Larocca A; Rossi D; Cavalli M; Genuardi M; Ria R; Gentili S; Patriarca F; Nozzoli C; Levi A; Guglielmelli T; Benevolo G; Callea V; Rizzo V; Cangialosi C; Musto P; De Rosa L; Liberati AM; Grasso M; Falcone AP; Evangelista A; Cavo M; Gaidano G; Boccadoro M; Palumbo A
    Blood; 2010 Dec; 116(23):4745-53. PubMed ID: 20807892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
    Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
    Reece DE; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Venkatakrishnan K; Neuwirth R; Riordan WJ; Karol M; von Moltke LL; Acharya M; Zannikos P; Keith Stewart A
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):57-67. PubMed ID: 20306195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
    Romano A; Chiarenza A; Consoli U; Conticello C; Forte S; Uccello G; Vetro C; Cavalli M; Coppolino F; Palumbo GA; Di Raimondo F
    Ann Oncol; 2013 Apr; 24(4):1038-44. PubMed ID: 23136226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
    Ahn JS; Jung SH; Lee SS; Ahn SY; Yang DH; Kim YK; Kim HJ; Lee JJ
    Biomed Res Int; 2014; 2014():145843. PubMed ID: 25530955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.